Novartis

News

Novartis' sickle cell drug gets Breakthrough Therapy designa...

The FDA has granted Breakthrough Therapy designation to Novartis' crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with

News

Novartis offers to buy Kymriah manufacturer

Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering t

News

Novartis oncology CEO quits after less than a year

Novartis has appointed Susanne Schaffert to lead its oncology division after incumbent CEO Liz Barrett decided to leave for another job.

News

Sandoz joins medical cannabis drive with Tilray deal

Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a global supply deal with Canadian producer Tilray.

News

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.

News

Novartis takes Xolair follow-up into phase III hives trial

Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, into a phase III programme on the strength of a mid-stage study.

Novartis' sickle cell drug gets Breakthrough Therapy designa...

Novartis offers to buy Kymriah manufacturer

Novartis oncology CEO quits after less than a year

Sandoz joins medical cannabis drive with Tilray deal

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

Novartis takes Xolair follow-up into phase III hives trial

Data builds on Roche's dominance in primary progressive MS

How to meet your physicians where they are online

Novartis

Editor's Picks